The instability index estimates a protein's in vitro stability, so the instability index must be below 40 for a protein to be considered stable
Many events appear consistent with those seen with approved products, while a distinct subset involves dosing errors, some requiring hospitalization
However, BBS is a rare disease with a small patient population for which there are no other targeted pharmacotherapies, and the 14-week, exploratory, placebo-controlled outcomes provide some supportive comparative effectiveness evidence
For MCI patient samples, the Petersen criteria [70] were commonly used to diagnose MCI, though other studies used revised Petersen criteria [71], or a combination of the Montreal Cognitive Assessment, DSM-IV, Clinical Dementia Rating, and Mini-Mental State Examination [34, 62]
Clinical Scenarios Favoring Monotherapy IGF-1 is 20-30% below the age-adjusted reference range but not severely deficient The patient is age 30% below range) | | Age | 50 | | Prior response to sermorelin | IGF-1 normalized at 12 weeks | IGF-1 unchanged or minimally changed | | Pituitary reserve assessment | Normal GH stimulation test | Subnormal peak GH on stimulation | | Cost tolerance | Lower | Higher | | Concurrent anabolic goals | Baseline wellness | Body recomposition, recovery | Dosing the Sermorelin + CJC-1295 Protocol No published RCT has evaluated the combination protocol head-to-head against monotherapy in adults
